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Botulism, caused by exposure to one or more of the eight serotypes of botulinum neurotoxins
(BoNTs) (BoNT/A through H), is often fatal without rapid treatment. Botulism occurs sporadically
all over the world, due to environmental exposure, contaminated food, wound infection, or overdose
from genuine or counterfeit BoNT-based drug products.
In the past few decades, cosmetic and medical uses for an ever-expanding list of disease
indications, from depression to spasticity [1], for BOTOX® [2] and other [3] approved BoNT-based
drugs, such as Myobloc®, Xeomin®, and others, has resulted in an explosive growth in both the
availability of BoNT and number of persons treated. Furthermore, intentional misuse of BoNTs by
bioterrorists [4] or rogue nations [5] remains a risk. With increasing BoNT production, and use and
mis-use, comes the need for treatment and prevention of BoNT intoxication.
In this special issue of “Botulinum Neurotoxins (BoNTs)—Antibody and Vaccine”, two review
articles and ten original research papers on medical countermeasures for botulism, and therapeutic
use of a new BoNT/A-based drug, are reported. Briefly, Grace Sundeen and Joseph T. Barbieri [6]
reviewed the current status of DNA-based, viral vector-based, and recombinant protein-based vaccines
against botulism. A vaccine is needed since the pentavalent toxoid vaccine is no longer available.
Christine Rasett-Escargueil, Arnaud Avril, and their colleagues [7] reviewed the status of the EU
Framework program for developing humanized AntibotABE antibodies. In this issue, we, along
with our collaborators at UCSF, report engineering of a tri-epitopic antibody that recapitulates the
neutralizing activity of a combination of three antibodies to BoNT/A, potentially offering a simpler
route to an antibody-based therapeutic [8]. Along with Consuelo Garcia-Rodriguez, we also report
development of a three-antibody combination that potently neutralizes BoNT/E [9], analogous to
that reported for BoNT/A and/F. Yagmur Derman, Katja Selby, and their collaborators across the EU
report on a humanized scFv-FC fusion, derived from immunized macaques and its potential in the
neutralization of BoNT/E [10]. Osnat Rosen, Amram Torgeman, Ran Zichel, and their team from Israel,
reported their development of an in vitro potency assay for selected anti-BoNT antibodies [11] and their
research on the role of homologous Fc fragment in the potency and efficacy of anti-BoNT antibody [12].
Fetweh H. Al-Saleem, Rashmi Sharma, Scott K. Dessain, and their co-workers from the United States
of America, presented the development of a fusion protein for red blood cell adherence of immune
complexes containing BoNT, to improve neutralization and macrophage uptake [13]. Nicola Bak,
Dorothea Sesardic, and their team from the United Kingdom, reported on the application of SiMa
cells for cell-based neutralization test for BoNT/A and BoNT/E [14]. On the vaccine development
side, Robert P. Webb, Theresa J. Smith, and their team from USAMRIID, reported on the production of
non-toxic holoproteins and recombinant BoNT toxin domain subunits as vaccine candidates against
multiple serotypes [15], Denis Y. Otaka, Felipe M. Salvarani, and their team from Brazil, reported
on the humoral response of buffalos to a recombinant vaccine against BoNT/C and D [16]. Finally,
Toxins 2018, 10, 495; doi:10.3390/toxins10120495 www.mdpi.com/journal/toxins
Toxins 2018, 10, 495 2 of 3
Hyun Jung Chang, Bo Young Hong, Jeong-Yi Kwon, and their teams from South Korea, report results
from a clinical trial on the efficacy and safety of Botulax for the treatment of dynamic equinus foot
deformity in children with cerebral palsy [17].
We hope the papers presented here will provide new insight into this intriguing protein,
and prevention or treatment of botulism. We appreciate the contributions of BoNT researchers from
around the world to this special issue.
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